The result from six studies with 457 CRC patients showed that no obvious association was found between CD166 expression and clinical stage (OR = 1.73, 95% CI = 0.91-3.27, P = 0.092) (Figure 6). This evidence concerns the gene ALCAM and colorectal carcinoma.